These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 18540572)

  • 1. In vivo characterization of progestins with reduced non-genomic activity in vitro.
    Otto C; Rohde-Schulz B; Schwarz G; Fuchs I; Klewer M; Altmann H; Fritzemeier KH
    Ernst Schering Found Symp Proc; 2007; (1):151-70. PubMed ID: 18540572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of the uterine and mammary gland effects of progesterone and medroxyprogesterone acetate.
    Otto C; Fuchs I; Vonk R; Fritzemeier KH
    Maturitas; 2010 Apr; 65(4):386-91. PubMed ID: 20036471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate.
    Otto C; Fuchs I; Altmann H; Klewer M; Walter A; Prelle K; Vonk R; Fritzemeier KH
    Endocrinology; 2008 Aug; 149(8):3952-9. PubMed ID: 18420741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas.
    Balañá ME; Lupu R; Labriola L; Charreau EH; Elizalde PV
    Oncogene; 1999 Nov; 18(46):6370-9. PubMed ID: 10597237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells.
    Purmonen S; Manninen T; Pennanen P; Ylikomi T
    Oncol Rep; 2008 Jun; 19(6):1627-34. PubMed ID: 18497975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro.
    Otto C; Fuchs I; Altmann H; Klewer M; Schwarz G; Bohlmann R; Nguyen D; Zorn L; Vonk R; Prelle K; Osterman T; Malmström C; Fritzemeier KH
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):95-100. PubMed ID: 18606537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of progestins of human proliferative endometrium: an in vitro model of potential clinical relevance.
    Illouz S; Dales JP; Sferlazzo K; Garcia S; Carpentier-Meunier S; Boubli L; Lavaut MN; Charpin C
    Int J Mol Med; 2003 Oct; 12(4):517-23. PubMed ID: 12964029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of progestins on human endometrium in vitro].
    Charpin C; Illouz S; Dales JP; Lavaut MN; Allasia C; Boubli L
    Bull Acad Natl Med; 2002; 186(1):125-45; discussion 145-6. PubMed ID: 12146137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
    Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
    Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of progestin-induced mammary-derived growth hormone in the pathogenesis of cystic endometrial hyperplasia in the bitch.
    Bhatti SF; Rao NA; Okkens AC; Mol JA; Duchateau L; Ducatelle R; van den Ingh TS; Tshamala M; Van Ham LM; Coryn M; Rijnberk A; Kooistra HS
    Domest Anim Endocrinol; 2007 Oct; 33(3):294-312. PubMed ID: 16956744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.
    Lanari C; Lüthy I; Lamb CA; Fabris V; Pagano E; Helguero LA; Sanjuan N; Merani S; Molinolo AA
    Cancer Res; 2001 Jan; 61(1):293-302. PubMed ID: 11196177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progestin modulation of estrogen-dependent marker protein synthesis in the endometrium.
    DeSombre ER; Kuivanen PC
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):6-11. PubMed ID: 3975654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay between progesterone and prolactin in mammary development and implications for breast cancer.
    Lee HJ; Ormandy CJ
    Mol Cell Endocrinol; 2012 Jun; 357(1-2):101-7. PubMed ID: 21945475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
    Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells.
    Ruan X; Neubauer H; Yang Y; Schneck H; Schultz S; Fehm T; Cahill MA; Seeger H; Mueck AO
    Climacteric; 2012 Oct; 15(5):467-72. PubMed ID: 22335423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sex steroids on proliferation in normal mammary tissue.
    Söderqvist G
    Ann Med; 1998 Dec; 30(6):511-24. PubMed ID: 9920352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestagens and mammary gland development: differentiation versus carcinogenesis.
    Russo IH; Russo J
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():7-12. PubMed ID: 1839345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.